216 related articles for article (PubMed ID: 33754208)
1. In search for biomarkers and potential drug targets for uterine serous endometrial cancer.
Dinoi G; Mariani A; Martinelli E; Ciucci A; Zannoni GF; Weaver AL; Keeney GL; Vasmatzis G; Anastasiadis PZ; Fanfani F; Scambia G; Gallo D
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1647-1658. PubMed ID: 33754208
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
Urick ME; Bell DW
Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
[TBL] [Abstract][Full Text] [Related]
3. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
Urick ME; Bell DW
Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
[TBL] [Abstract][Full Text] [Related]
4. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma.
Beirne JP; Quinn JE; Maxwell P; Kalloger SE; McAlpine J; Gilks CB; Harley IJ; McCluggage WG
Int J Gynecol Cancer; 2013 Jan; 23(1):113-8. PubMed ID: 23221734
[TBL] [Abstract][Full Text] [Related]
6. The frequency and significance of WT-1 expression in serous endometrial carcinoma.
Hedley C; Sriraksa R; Showeil R; Van Noorden S; El-Bahrawy M
Hum Pathol; 2014 Sep; 45(9):1879-84. PubMed ID: 25033726
[TBL] [Abstract][Full Text] [Related]
7. [Application of immunohistochemistry in differential diagnosis of endometrial carcinoma].
Wu HW; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):784-8. PubMed ID: 23302346
[No Abstract] [Full Text] [Related]
8. Outcome in serous ovarian cancer is not associated with LATS expression.
Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
[TBL] [Abstract][Full Text] [Related]
9. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
10. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ
Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776
[TBL] [Abstract][Full Text] [Related]
11. The immunohistochemical profile of atypical eosinophilic syncytial changes vs serous carcinoma.
Haley SL; Malhotra RK; Qiu S; Eltorky ME
Ann Diagn Pathol; 2011 Dec; 15(6):402-6. PubMed ID: 21855381
[TBL] [Abstract][Full Text] [Related]
12. A 4-gene signature predicts prognosis of uterine serous carcinoma.
Chen H; Li L; Qin P; Xiong H; Chen R; Zhang M; Jiang Q
BMC Cancer; 2021 Feb; 21(1):154. PubMed ID: 33579221
[TBL] [Abstract][Full Text] [Related]
13. Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.
Kakimoto S; Miyamoto M; Einama T; Matsuura H; Iwahashi H; Ishibashi H; Sakamoto T; Hada T; Takano M
Pathol Oncol Res; 2020 Oct; 26(4):2299-2306. PubMed ID: 32468249
[TBL] [Abstract][Full Text] [Related]
14. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
15. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H
BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178
[TBL] [Abstract][Full Text] [Related]
16. Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation.
Xiao Z; He Y; Liu C; Xiang L; Yi J; Wang M; Shen T; Shen L; Xue Y; Shi H; Liu P
Oncol Rep; 2019 May; 41(5):2667-2678. PubMed ID: 30896884
[TBL] [Abstract][Full Text] [Related]
17. CD44 expression in papillary serous endometrial carcinoma.
Hosford S; Elliott J; Ma ZW; Majeste R; Dubeshter B
Int J Gynecol Cancer; 2003; 13(4):480-4. PubMed ID: 12911725
[TBL] [Abstract][Full Text] [Related]
18. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
Zhang J; Wang JC; Li YH; Wang RX; Fan XM
Chin Med J (Engl); 2017 Feb; 130(3):280-287. PubMed ID: 28139510
[TBL] [Abstract][Full Text] [Related]
19. Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning.
Nolin AC; Tian C; Hamilton CA; Casablanca Y; Bateman NW; Chan JK; Cote ML; Shriver CD; Powell MA; Phippen NT; Conrads TP; Maxwell GL; Darcy KM
Gynecol Oncol; 2022 Jul; 166(1):90-99. PubMed ID: 35624045
[TBL] [Abstract][Full Text] [Related]
20. ER+ /PR+ /TFF3+ /IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases.
Mhawech-Fauceglia P; Yan L; Liu S; Pejovic T
Histopathology; 2013 Jun; 62(7):976-85. PubMed ID: 23570281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
